Tuesday, March 31 2026

Pharma sector: Leading Russian insulin maker to invest USD80m
The leading Russian pharmaceutical company M/s Genetics Pharmaceuticals/M/s Zavod Medsintez LLC, producing insulin, will invest approximately USD80 million in Pakistan’s pharma sector over the next six years. In this connection, the Drug Regulatory Authority of Pakistan (DRAP) has conditionally fixed the Maximum Retail Price (MRP) for six insulin products of the Russian pharmaceutical company, namely M/s Genetics Pharmaceuticals/M/s Zavod Medsintez LLC, while directing the company to immediately start working on the construction of local manufacturing plants and fully complete it by December 2031.
Related news categories: business economic-indicators misc pharma